<DOC>
	<DOCNO>NCT00833794</DOCNO>
	<brief_summary>The purpose study compare analgesic efficacy , safety clinical benefit Tramadol OAD tablets versus Placebo .</brief_summary>
	<brief_title>A Two-Arm Study Comparing Analgesic Efficacy Safety Tramadol HCl Once-a-Day Versus Placebo Treatment Pain Due Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Inclusion Criteria OpenLabel phase : 1 . Males females 2 . Must age 4080 3 . Must meet American College Rheumatology ( ACR ) Clinical Classification Criteria Osteoarthritis Knee : Current knee pain Less 30 minute morning stiffness without crepitus active motion Confirmation either arthroscopy radiologist 's report ( Xrays show osteophyte , joint space narrow subchondral bone sclerosis { eburnation } ) within five year prior entry study 4 . Must history exposure treatment ( pain due osteoarthritis ( OA ) knee ) Nonsteroidal antiinflammatory drug ( NSAIDs ) , COX II inhibitor tramadol . 5 . Must take one medication regular basis 30 day prior Visit 2 ( S0 ) . 6 . Must meet follow criterion severity pain Visit 2 ( Day S0 ) : Have score ≥ 4 11point Numerical Rating Scale ( PINRS ; range : 010 ) Have total increase ≥ 2 point 11point Numerical Rating Scale ( range : 010 ) compare rating Visit 1 ( Day SX ) 7 . Must erythrocyte sedimentation rate ( ESR ) &lt; 40 mm/hr 8 . Must oral write language comprehension level sufficient comply protocol complete studyrelated material 9 . Must sign date approve write Informed Consent form French , Spanish , English Romanian , also sign date Investigator ( unless otherwise require ethic committee ) , prior study participation Exclusion Criteria OpenLabel phase : 1 . Has know rheumatoid arthritis rheumatic disease 2 . Has secondary arthritis i.e . follow : septic arthritis ; inflammatory joint disease ; gout ; pseudogout ; Paget 's disease ; target joint fracture ; acromegaly ; fibromyalgia ; Wilson 's disease ; Ochronosis ; Haemochromatosis ; Osteochondromatosis ; heritable arthritic disorder ; collagen gene mutation 3 . Has history bursitis knee ( target knee ) 4 . Has history pain ipsilateral hip ( target knee ) 5 . Has meniscal tear target knee within last 12 month 6 . Has cartilage reconstruction procedure target knee 7 . Has therapeutic arthroscopy procedure target knee within last 12 month 8 . Has Body Mass Index ( BMI ) great 37 9 . Has major illness , require hospitalisation 3 month commencement screen period 10 . Is unwilling stop take pain medication study medication ( arthritis type pain ) unwilling stop take medication treatment OA 11 . Has previously fail treatment tramadol discontinue treatment tramadol due adverse event 12 . Has take opioids ( e.g . codeine , oxycodone , hydromorphone , etc . ) treatment OA chronic condition 13 . Has receive Corticosteroid Injections target knee within last 3 month Viscous injection target knee within last 6 month 14 . Has treatment within last 3 week follow medication : monoamine oxidase inhibitor ; tricyclic antidepressant tricyclic compound ( e.g . cyclobenzaprine , promethazine ) ; neuroleptic ; selective serotonin reuptake inhibitor ; serotoninnorepinephrine reuptake inhibitor drug reduces seizure threshold 15 . Has treatment another investigational agent within last 30 day 16 . Has history seizure disorder Infantile Febrile Seizures 17 . Has previous current opioid dependency 18 . Has bowel disease cause malabsorption 19 . Is pregnant , lactate childbearing potential unwilling utilise medically approve method contraception participation clinical trial 20 . Has significant liver disease , define active hepatitis elevate liver enzymes &gt; 3 time upper boundary normal range 21 . Has significant renal disease ( defined creatinine clearance &lt; 30 mL/min 22 . Has history current past substance abuse dependence , nicotine 23 . Has know document allergy tramadol structurally similar drug ( e.g . opiate ) 24 . Has know document allergy acetaminophen structurally similar drug 25 . Has condition , opinion Investigators , would adversely affect patient 's ability complete study measure . Inclusion criterion doubleblinded phase : Patients must continue meet openlabel eligibility criterion Must score ≥ 4 Numerical Rating Scale ( NRS ) total increase ≥ 2 point NRS compare Visit 3 ( Day R14 ) Must take prohibited medication Openlabel Phase . Exclusion criterion doubleblinded phase : Patient Request Adverse Events contraindicate administration study medication Any situation opinion Investigator continue participation study would patient 's best interest .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>